Estimated antiretroviral therapy coverage among people living with HIV in Greece
Greece: Estimated antiretroviral therapy coverage among people living with HIV was 68.0% in 2025. ▲ Rising
Estimated antiretroviral therapy coverage among people living with HIV in Greece, 2000–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Greece recorded 68.0% for estimated antiretroviral therapy coverage among people living with hiv in 2025.
That represents a change of up 1.5% over ten years.
Over the whole period, estimated antiretroviral therapy coverage among people living with hiv in Greece peaked at 72.0% in 2017 and was at its lowest, 46.0%, in 2003.
That places Greece 90th out of 143 countries with data for 2025, putting it in the middle of the range.
The long-run direction has been consistently rising across the 26 years of available data.
Estimated antiretroviral therapy coverage among people living with HIV in Greece, year by year
| Year | Value | Change |
|---|---|---|
| 2000 | 47.0% | — |
| 2001 | 47.0% | +0.0% |
| 2002 | 47.0% | +0.0% |
| 2003 | 46.0% | -2.1% |
| 2004 | 46.0% | +0.0% |
| 2005 | 46.0% | +0.0% |
| 2006 | 46.0% | +0.0% |
| 2007 | 47.0% | +2.2% |
| 2008 | 48.0% | +2.1% |
| 2009 | 49.0% | +2.1% |
| 2010 | 50.0% | +2.0% |
| 2011 | 53.0% | +6.0% |
| 2012 | 55.0% | +3.8% |
| 2013 | 59.0% | +7.3% |
| 2014 | 63.0% | +6.8% |
| 2015 | 67.0% | +6.3% |
| 2016 | 71.0% | +6.0% |
| 2017 | 72.0% | +1.4% |
| 2018 | 71.0% | -1.4% |
| 2019 | 70.0% | -1.4% |
| 2020 | 69.0% | -1.4% |
| 2021 | 69.0% | +0.0% |
| 2022 | 68.0% | -1.4% |
| 2023 | 68.0% | +0.0% |
| 2024 | 68.0% | +0.0% |
| 2025 | 68.0% | +0.0% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 46.9% | 46.0% | 49.0% | 10 |
| 2010s | 63.1% | 50.0% | 72.0% | 10 |
| 2020s | 68.3% | 68.0% | 69.0% | 6 |
Countries ranked near Greece
More health data for Greece
- Un projection of annual infant deaths, annual growth rate -4 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.0227 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,321 deaths per 1,000 people (2090)
- Number of infants who die before age 1 24 deaths (2100)
- Population ages 15-19, male, annual growth rate 2.35 % change on previous year (2025)
- Population ages 15-19, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 15-19, male, per capita 0.0277 units per person (2025)
- Population ages 20-24, female, annual growth rate 1.42 % change on previous year (2025)
- Population ages 20-24, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 20-24, female, per capita 0.0245 units per person (2025)
Frequently asked questions
- What is estimated antiretroviral therapy coverage among people living with hiv in Greece?
- Estimated antiretroviral therapy coverage among people living with hiv in Greece was 68.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest estimated antiretroviral therapy coverage among people living with hiv recorded in Greece?
- The highest recorded value was 72.0% in 2017.
- What is the lowest estimated antiretroviral therapy coverage among people living with hiv recorded in Greece?
- The lowest recorded value was 46.0% in 2003.
- How does Greece rank for estimated antiretroviral therapy coverage among people living with hiv?
- Greece ranks 90th out of 143 countries with data for 2025.
- Is estimated antiretroviral therapy coverage among people living with hiv rising or falling in Greece?
- Over the last ten years it is up 1.5%. The long-run trend across the full record is rising.
- Where does this Greece data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Estimated antiretroviral therapy coverage among people living with HIV (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 26 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).